Tau oligomers: The toxic player at synapses in Alzheimer’s disease

Frontiers in Cellular Neuroscience

Volumn 9, Issue DEC, 2015, Pages 1-10

  Guerrero Muñoz, Marcos J ^a   Gerson, Julia ^a   Castillo Carranza, Diana L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer s disease; A oligomers; Dendrites; Synapsis; Tau oligomers

Indexed keywords

AMYLOID BETA PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN;

ALZHEIMER DISEASE; DENDRITE; DIFFUSE LEWY BODY DISEASE; ELECTROPHYSIOLOGY; HIPPOCAMPAL CA3 REGION; HUMAN; INTERNALIZATION; LONG TERM DEPRESSION; MOLECULAR INTERACTION; MOSSY FIBER; NERVE CELL PLASTICITY; NERVE FIBER; NEUROMUSCULAR DISEASE; NONHUMAN; OLIGOMERIZATION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SYNAPSE; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; TAUOPATHY;

EID: 84954047109     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2015.00464     Document Type: Review

References (140)

1. Ahmed, Z., Cooper, J., Murray, T., Garn, K., McNaughton, E., Clarke, H., et al. (2014). A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127, 667-683. doi: 10.1007/s00401-014-1254-6
2. Alldred, M. J., Duff, K. E., and Ginsberg, S. D. (2012). Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol. Dis. 45,751-762.doi: 10.1016/j.nbd.2011.10.022
3. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., et al. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590. doi: 10.1046/j.1471-4159.2003.01879.x
4. Arendt, T., Stieler, J., Strijkstra, A. M., Hut, R. A., Rudiger, J., Van der Zee, E. A., et al. (2003). Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J. Neurosci. 23, 6972-6981.
5. Arriagada, P. V., Marzloff, K., and Hyman, B. T. (1992). Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 42, 1681-1688. doi: 10.1212/WNL.42.9.1681
6. Baglioni, S., Casamenti, F., Bucciantini, M., Luheshi, L. M., Taddei, N., Chiti, F., et al. (2006). Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J. Neurosci. 26, 8160-8167. doi: 10.1523/JNEUR0SCI.4809-05.2006
7. Barghorn, S., and Mandelkow, E. (2002). Toward a Unified Scheme for the Aggregation of Tau into Alzheimer Paired Helical Filamentsf. Biochemistry 41, 14885-14896. doi: 10.1021/bi026469j
8. Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., et al. (2007). Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662. doi: 10.1523/JNEUROSCI.0587-07.2007
9. Bhaskar, K., Yen, S. H., and Lee, G. (2005). Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 280, 35119-35125. doi: 10.1074/jbc.M505895200
10. Bjorklund, N. L., Sadagoparamanujam, R. L., Ghirardi, V.-M., Woltjer, V., and Taglialatela, G. (2012). Absence of amyloid pp oligomers at the postsynapse and regulated synaptic Zn2++ in cognitively intact aged individuals with Alzheimer’s disease neuropathology. Mol. Neurodegener. 7:23. doi: 10.1186/1750-1326-7-23
11. Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., et al. (2007). Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am. J. Pathol. 171, 2012-2020. doi: 10.2353/ajpath.2007.070403
12. Braak, H., and Braak, E. (1991a). Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1, 213-216. doi: 10.1111/j.1750-3639.1991.tb00661.x
13. Braak, H., and Braak, E. (1991b). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259. doi: 10.1007/BF00308809
14. Braak, H., and Braak, E. (1996). Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol. Scand. Suppl. 165, 3-12. doi: 10.1111/j.1600-0404.1996.tb05866.x
15. Brion, J. P., Octave, J. N., and Couck, A. M. (1994). Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. Neuroscience 63, 895-909. doi: 10.1016/0306-4522(94)90533-9
16. Burrè, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M., and Südhof, T. C.. (2010). αα-Synuclein Promotes SNARE-Complex Assembly in vivo and in vitro. Science 329, 1663-1667. doi: 10.1126/science.1195227
17. Calafate, S., Buist, A., Miskiewicz, K., Vijayan, V., Daneels, G., de Strooper, B., et al. (2015). Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 11, 1176-1183. doi: 10.1016/j.celrep.2015.04.043
18. Cappai, R., and Barnham, K. J. (2008). Delineating the mechanism of Alzheimer’s disease A beta peptide neurotoxicity. Neurochem. Res. 33, 526-532. doi: 10.1007/s11064-007-9469-8
19. Castillo-Carranza, D. L., Guerrero-Munoz, M. J., Sengupta, U., Hernandez, C., Barret, A., Dineley, K. T., et al. (2015). Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an AD mouse model. J. Neurosci. 35, 4857-4868. doi: 10.1523/JNEUR0SCI.4989-14.2015
20. Chabrier, M. A., Blurton-Jones, M., Agazaryan, A. A., Nerhus, J. L., Martinez-Coria, H., and LaFerla, F. M. (2012). Soluble abeta promotes wild-type tau pathology in vivo. J. Neurosci. 32, 17345-17350. doi: 10.1523/JNEUR0SCI.0172-12.2012
21. Chabrier, M. A., Cheng, D., Castello, N. A., Green, K. N., and LaFerla, F. M. (2014). Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer’s disease. Neurobiol. Dis. 64, 107-117. doi: 10.1016/j.nbd.2014.01.007
22. Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., et al. (2007). Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828. doi: 10.1074/jbc.M701078200
23. Chin, J., Palop, J. J., Puolivali, J., Massaro, C., Bien-Ly, N., Gerstein, H., et al. (2005). Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 25, 9694-9703. doi: 10.1523/JNEUR0SCI.2980-05.2005
24. Chin, J., Palop, J. J., Yu, G. Q., Kojima, N., Masliah, E., and Mucke, L. (2004). Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24, 4692-4697. doi: 10.1523/JNEUR0SCI.0277-04.2004
25. Chirita, C. N., Congdon, E. E., Yin, H., and Kuret, J. (2005). Triggers of full-length tau aggregation:? a role for partially folded intermediatesf. Biochemistry 44, 5862-5872. doi: 10.1021/bi0500123
26. Chirita, C. N., Necula, M., and Kuret, J. (2003). Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278, 25644-25650. doi: 10.1074/jbc.M301663200
27. Cowan, C. M., Bossing, T., Page, A., Shepherd, D., and Mudher, A. (2010). Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 120, 593-604. doi: 10.1007/s00401-010-0716-8
28. Crimins, J. L., Pooler, A., Polydoro, M., Luebke, J. I., and Spires-Jones, T. L.. (2013). The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res. Rev. 12, 757-763. doi: 10.1016/j.arr.2013.03.002
29. Crimins, J. L., Rocher, A. B., and Luebke, J. I. (2012). Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol. 124, 777-795. doi: 10.1007/s00401-012-1038-9
30. Crimins, J. L., Rocher, A. B., Peters, A., Shultz, P., Lewis, J., and Luebke, J. I. (2011). Homeostatic responses by surviving cortical pyramidal cells in neurodegenerative tauopathy. Acta Neuropathol. 122, 551-564. doi: 10.1007/s00401-011-0877-0
31. de Calignon, A., Polydoro, M., Suarez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., et al. (2012). Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697. doi: 10.1016/j.neuron.2011.11.033
32. Decker, J. M., Kruger, L., Sydow, A., Zhao, S., Frotscher, M., Mandelkow, E., et al. (2015). Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++++) dysregulation. Acta Neuropathol. Commun. 3:23. doi: 10.1186/s40478-015-0193-3
33. De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., et al. (2008). Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 29, 1334-1347. doi: 10.1016/j.neurobiolaging.2007.02.029
34. Diaz-Hernandez, M., Gomez-Ramos, A., Rubio, A., Gomez-Villafuertes, R., Naranjo, J. R., Miras-Portugal, M. T., et al. (2010). Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J. Biol. Chem. 285, 32539-32548. doi: 10.1074/jbc.M110.145003
35. Dickstein, D., Brautigam, H., Stockton, S. Jr., Schmeidler, J., and Hof, P. (2010). Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct. Funct. 214, 161-179. doi: 10.1007/s00429-010-0245-1
36. Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M., and Gotz, J. (2003). beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J. Biol. Chem. 278, 40162-40168. doi: 10.1074/jbc.M308243200
37. Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., et al. (2014). Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J. Neurosci. 34, 6084-6097. doi: 10.1523/JNEUR0SCI.4261-13.2014
38. Gerson, J., Sengupta, U., Lasagna-Reeves, C., Guerrero-Munoz, M., Troncoso, J., and R. Kayed. (2014). Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2:73 doi: 10.1186/2051-5960-2-73
39. Gerson, J. E., and Kayed, R. (2013). Formation and propagation of tau oligomeric seeds. Front. Neurol. 4:93. doi: 10.3389/fneur.2013.00093
40. Giannakopoulos, P., Herrmann, F. R., Bussiere, T., Bouras, C., Kovari, E., Perl, D. P., et al. (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 60, 1495-1500. doi: 10.1212/01.WNL.0000063311.58879.01
41. Goedert, M., Jakes, R., and Crowther, R. A. (1999). Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBSLett. 450, 306-311. doi: 10.1016/S0014-5793(99)00508-6
42. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., et al. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann. Neurol. 41, 17-24. doi: 10.1002/ana.410410106
43. Gomez-Ramos, A., Diaz-Hernandez, M., Rubio, A., Diaz-Hernandez, J. I., Miras-Portugal, M. T., and Avila, J. (2009). Characteristics and consequences of muscarinic receptor activation bytau protein. Eur. Neuropsychopharmacol. 19, 708-717. doi: 10.1016/j.euroneuro.2009.04.006
44. Gomez-Ramos, A., Diaz-Hernandez, M., Rubio, A., Miras-Portugal, M. T., and Avila, J. (2008). Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci. 37, 673-681. doi: 10.1016/j.mcn.2007.12.010
45. Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R. M. (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495. doi: 10.1126/science.1062097
46. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112. doi: 10.1038/nrm2101
47. Hamilton, R. L. (2000). Lewy bodies in alzheimer's disease: a neuropathological review of 145 cases using aa-synuclein immunohistochemistry. Brain Pathol. 10, 378-384. doi: 10.1111/j.1750-3639.2000.tb00269.x
48. Handoko, M., Grant, M., Kuskowski, M., Zahs, K. R., Wallin, A., Blennow, K., et al. (2013).Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. 70, 594-599. doi: 10.1001/jamaneurol.2013.48
49. Hardy, J. (2009). The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 110, 1129-1134. doi: 10.1111/j.1471-4159.2009.06181.x
50. Hardy, J., and Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 12, 383-388. doi: 10.1016/0165-6147(91)90609-V
51. Harris, J. A., Koyama, A., Maeda, S., Ho, K., Devidze, N., Dubal, D. B., et al. (2012). Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS ONE 7:e45881. doi: 10.1371/journal.pone.0045881
52. Himmelstein, D. S., Ward, S. M., Lancia, J. K., Patterson, K. R., and Binder, L. I. (2012). Tau as a therapeutic target in neurodegenerative disease. Pharmacol. Ther. 136, 8-22. doi: 10.1016/j.pharmthera.2012.07.001
53. Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081. doi: 10.1016/j.neuron.2010.11.030
54. Hunsberger, H. C., Rudy, C. C., Batten, S. R., Gerhardt, G. A., and Reed, M. N. (2015). P301L tau expression affects glutamate release and clearance in the hippocampal trisynaptic pathway. J. Neurochem. 132, 169-182. doi: 10.1111/jnc.12967
55. Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., et al. (2004). Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931. doi: 10.1212/01.WNL.0000115115.98960.37
56. Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., et al. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142, 387-397. doi: 10.1016/j.cell.2010.06.036
57. Jankowsky, J. L., Melnikova, T., Fadale, D. J., Xu, G. M., Slunt, H. H., Gonzales, V., et al. (2005). Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer’s disease. J. Neurosci. 25, 5217-5224. doi: 10.1523/JNEUR0SCI.5080-04.2005
58. Jankowsky, J. L., Xu, G., Fromholt, D., Gonzales, V., and Borchelt, D. R. (2003). Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 1220-1227.
59. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011). Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108,5819-5824. doi: 10.1073/pnas.1017033108
60. Jucker, M., and Walker, L. C. (2011). Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532-540. doi: 10.1002/ana.22615
61. Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., et al. (2015). Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol. 77, 953-971. doi: 10.1002/ana.24394
62. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489. doi: 10.1126/science.1079469
63. Kimura, T., Whitcomb, D. J., Jo, J., Regan, P., Piers, T., Heo, S., et al. (2014). Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2:369.
64. King, M. E., Gamblin, T. C., Kuret, J., and Binder, L. I. (2000). Differential assembly of human tau isoforms in the presence of arachidonic acid. J. Neurochem. 74, 1749-1757. doi: 10.1046/j.1471-4159.2000.0741749.x
65. Komuro, Y., Xu, G., Bhaskar, K., and Lamb, B. T. (2015). Human tau expression reduces adult neurogenesis in a mouse model of tauopathy. Neurobiol. Aging 36, 2034-2042. doi: 10.1016/j.neurobiolaging.2015.03.002
66. Kopeikina, K. J., Carlson, G. A., Pitstick, R., Ludvigson, A. E., Peters, A., Luebke, J. I., et al. (2011). Tau Accumulation Causes Mitochondrial Distribution Deficits in Neurons in a Mouse Model of Tauopathy and in Human Alzheimer’s Disease Brain. Am. J. Pathol. 179, 2071-2082. doi: 10.1016/j.ajpath.2011.07.004
67. Kopeikina, K. J., Wegmann, S., Pitstick, R., Carlson, G. A., Bacskai, B. J., Betensky, R. A., et al. (2013). Tau causes synapse loss without disrupting calcium homeostasis in the rTg4510 model of tauopathy. PLoS ONE 8:e80834. doi: 10.1371/journal.pone.0080834
68. Kuchibhotla, K. V., Wegmann, S., Kopeikina, K. J., Hawkes, J., Rudinskiy, N., Andermann, M. L., et al. (2014). Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. U.S.A.111, 510-514. doi: 10.1073/pnas.1318807111
69. Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., et al. (2012). Soluble aa-synuclein is a novel modulator of alzheimer’s disease pathophysiology. J. Neurosci. 32, 10253-10266. doi: 10.1523/JNEUR0SCI.0581-12.2012
70. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R., and Kayed, R. (2010). Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041. doi: 10.1021/bi1016233
71. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., and Kayed, R. (2011). Tau Oligomers Impair Memory and Induce Synaptic and Mitochondrial Dysfunction in Wild-type Mice. Mol. Neurodegener. 6:39. doi: 10.1186/1750-1326-6-39
72. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., et al. (2012a). Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700. doi: 10.1038/srep00700
73. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., et al. (2012b). Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J. 26, 1946-1959. doi: 10.1096/fj.11-199851
74. Lee, G., Newman, S. T., Gard, D. L., Band, H., and Panchamoorthy, G. (1998). Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 111(Pt 21), 3167-3177.
75. Lee, J., Culyba, E. K., Powers, E. T., and Kelly, J. W. (2011). Amyloid-beta forms fibrils bynucleated conformational conversion ofoligomers. Nat. Chem. Biol. 7, 602-609. doi: 10.1038/nchembio.624
76. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357. doi: 10.1038/nature04533
77. Lesne, S., Kotilinek, L., and Ashe, K. H. (2008). Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151, 745-749. doi: 10.1016/j.neuroscience.2007.10.054
78. Lesne, S. E. (2013). Breaking the code of amyloid-oligomers. Int. J. Cell Biol. 2013:950783. doi: 10.1155/2013/950783
79. Liu, L., Drouet, V., Wu, J. W., Witter, M. P., Small, S. A., Clelland, C., et al. (2012). Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7:e31302. doi: 10.1371/journal.pone.0031302
80. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.Am. J. Pathol. 155, 853-862. doi: 10.1016/S0002-9440(10)65184-X
81. Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., and Takashima, A. (2006). Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci. Res. 54, 197-201. doi: 10.1016/j.neures.2005.11.009
82. Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., et al. (2007). Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861. doi: 10.1021/bi061359o
83. Maurin, H., Chong, S.-A., Kraev, I., Davies, H., Kremer, A., Seymour, C. M., et al. (2014). Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy. PLoS ONE 9:e87605. doi: 10.1371/journal.pone.0087605
84. Maurin, H., Seymour, C. M., Lechat, B., Borghgraef, P., Devijver, H., Jaworski, T., et al. (2013). Tauopathy differentially affects cell adhesion molecules in mouse brain: early down-regulation of nectin-3 in stratum lacunosum moleculare. PLoS ONE 8:e63589. doi: 10.1371/journal.pone.0063589
85. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46, 860-866. doi: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.C0;2-M
86. McLellan, M. E., Kajdasz, S. T., Hyman, B. T., and Bacskai, B. J. (2003). In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 23, 2212-2217.
87. Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, Rozkalne, A., Koenigsknecht-Talboo, J., et al. (2008). Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 451, 720-724. doi: 10.1038/nature06616
88. Miller, E. C., Teravskis, P. J., Dummer, B. W., Zhao, X., Huganir, R. L., and Liao, D.. (2014).Tau phosphorylation and tau mislocalization mediate soluble Abeta oligomer-induced AMPA glutamate receptor signaling deficits. Eur. J. Neurosci. 39, 1214-1224. doi: 10.1111/ejn.12507
89. Mondragòn-Rodrìguez, S., Trillaud-Doppia, E., Dudilot, A., Bourgeois, C., Lauzon, M., Leclerc, N., et al. (2012). Interaction of endogenous tau protein with synaptic proteins is regulated by n-methyl-d-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 287, 32040-32053. doi: 10.1074/jbc.M112.401240
90. Moreno, H., Choi, S., Yu, E., Brusco, J., Avila, J., Moreira, J. E., et al. (2011). Blocking effects of human tau on squid giant synapse transmission and its prevention by T-817 MA. Front Synaptic Neurosci 3:3. doi: 10.3389/fnsyn.2011.00003
91. Mufson, E. J., Ward, S., and Binder, L. (2014). Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer’s disease. Neurodegener. Dis. 13, 151-153. doi: 10.1159/000353687
92. Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., et al. (2015). Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain. 138, 1370-1381. doi: 10.1093/brain/awv0500
93. ddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P., and LaFerla, F. M. (2003). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging 24, 1063-1070. doi: 10.1016/j.neurobiolaging.2003.08.012
94. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., and LaFerla, F. M. (2006). Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413-39423. doi: 10.1074/jbc.M608485200
95. Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., et al. (2011). Characterization ofprefibrillar tau oligomers in vitro and in Alzheimers disease. J. Biol. Chem. 286, 23063-23076. doi: 10.1074/jbc.M111.237974
96. Perez-Nievas, B. G., Stein, T. D., Tai, H. C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., et al. (2013). Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain 136(Pt 8), 2510-2526. doi: 10.1093/brain/awt171
97. Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., and Davies, P. (2009). Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 29, 10741-10749. doi: 10.1523/JNEUR0SCI.1065-09.2009
98. Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W., and Hanger, D. P. (2013). Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389-394. doi: 10.1038/embor.2013.15
99. Regan, P., Piers, T., Yi, J.-H., Kim, D.-H., Huh, S., Park, S. J., et al. (2015).Tau phosphorylation at serine 396 residue is required for hippocampal ltd. J. Neurosci. 35, 4804-4812. doi: 10.1523/JNEUR0SCI.2842-14.2015
100. Reitz, C., and Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 88, 640-651. doi: 10.1016/j.bcp.2013.12.024
101. Reynolds, C. H., Garwood, C. J., Wray, S., Price, C., Kellie, S., Perera, T., et al. (2008). Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J. Biol. Chem. 283, 18177-18186. doi: 10.1074/jbc.M709715200
102. Riederer, B. (2001). Differential phosphorylation of tau proteins during kitten brain development and Alzheimer’s disease. J. Neurocytol. 30, 145-158. doi: 10.1023/A:1011991207942
103. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., et al. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316, 750-754. doi: 10.1126/science.1141736
104. Rocher, A. B., Crimins, J. L., Amatrudo, J. M., Kinson, M. S., Todd-Brown, M. A., Lewis, J., et al. (2010). Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp. Neurol. 223, 385-393. doi: 10.1016/j.expneurol.2009.07.029
105. Rosner, H., Rebhan, M., Vacun, G., and Vanmechelen, E. (1995). Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. Int. J. Dev. Neurosci. 13, 607-617. doi: 10.1016/0736-5748(95)00042-F
106. Ruschak, A. M., and Miranker, A. D. (2009). The role of prefibrillar structures in the assembly of a peptide amyloid. J. Mol. Biol. 393, 214-226. doi: 10.1016/j.jmb.2009.06.026
107. Sahara, N., Maeda, S., Murayama, M., Suzuki, T., Dohmae, N., Yen, S.-H., et al. (2007). Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur. J. Neurosci. 25, 3020-3029. doi: 10.1111/j.1460-9568.2007.05555.x
108. Sahara, N., Maeda, S., and Takashima, A. (2008). Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration. Curr. Alzheimer Res. 5, 591-598. doi: 10.2174/156720508786898442
109. SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481. doi: 10.1126/science.1113694
110. Sengupta, U., Guerrero-Munoz, M. J., Castillo-Carranza, D. L., Lasagna-Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., et al. (2015). Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol. Psychiatry 78, 672-683. doi: 10.1016/j.biopsych.2014.12.019
111. Serrano-Pozo, A., Frosch, M. P., Masliah, E., and Hyman, B. T. (2011a). Neuropathological alterations in Alzheimer disease. Cold SpringHarb Perspect. Med. 1:a006189. doi: 10.1101/cshperspect.a006189
112. Serrano-Pozo, A., Mielke, M. L., Gomez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., et al. (2011b). Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am. J. Pathol. 179, 1373-1384. doi: 10.1016/j.ajpath.2011.05.047
113. Shahani, N., Subramaniam, S., Wolf, T., Tackenberg, C., and Brandt, R. (2006). Tau aggregation and progressive neuronal degeneration in the absence ofchanges in spine density and morphology after targeted expression of alzheimer's diseaserelevant tau constructs in organotypic hippocampal slices. J. Neurosci. 26, 6103-6114. doi: 10.1523/JNEUR0SCI.4245-05.2006
114. Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875. doi: 10.1523/JNEUR0SCI.4970-06.2007
115. Small, S. A., and Duff, K. (2008). Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron 60, 534-542. doi: 10.1016/j.neuron.2008.11.007
116. Sokolow, S., Henkins, K. M., Bilousova, T., Miller, C. A., Vinters, H. V., Poon, W., et al. (2012). AD synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol. Aging 33, 15451555. doi: 10.1016/j.neurobiolaging.2011.05.011
117. Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration. LancetNeurol. 12, 609-622. doi: 10.1016/S1474-4422(13)70090-5
118. Spires, T. L., 0rne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., et al. (2006). Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 168, 1598-1607. doi: 10.2353/ajpath.2006.050840
119. Sydow, A., Van der Jeugd, A., Zheng, F., Ahmed, T., Balschun, D., Petrova, O., et al. (2011). Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J. Neurosci. 31, 2511-2525. doi: 10.1523/JNEUR0SCI.5245-10.2011
120. Tackenberg, C., and Brandt, R. (2009). Divergent pathways mediate spine alterations and cell death induced by amyloid-pp, wild-type tau, and R406W Tau. J. Neurosci. 29, 14439-14450. doi: 10.1523/JNEUR0SCI.3590-09.2009
121. Tackenberg, C., Grinschgl, S., Trutzel, A., Santuccione, A. C., Frey, M. C., Konietzko, U., et al. (2013). NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis. 4:e608. doi: 10.1038/cddis.2013.129
122. Tai, H. C., Serrano-Pozo, A., Hashimoto, T., Frosch, M. P., Spires-Jones, T. L., and Hyman, B. T. (2012). The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol. 181, 1426-1435. doi: 10.1016/j.ajpath.2012.06.033
123. Tai, H.-C., Wang, B. Y., Serrano-Pozo, A., Frosch, M. P., Spires-Jones, T. L., and Hyman, B. T. (2014). Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer’s disease. Acta Neuropathol. Commun. 2:146. doi: 10.1186/s40478-014-0146-2
124. Tang, Z., Ioja, E., Bereczki, E., Hultenby, K., Li, C., Guan, Z., et al. (2015). mTor mediates tau localization and secretion: Implication for Alzheimer’s disease. Biochim. Biophys. Acta 1853, 1646-1657. doi: 10.1016/j.bbamcr.2015.03.003
125. Terry, R. D. (2000). Do neuronal inclusions kill the cell? J. Neural Transm. Suppl. 59, 91-93. doi: 10.1007/978-3-7091-6781-6_12
126. Thorns, V., Hansen, L., and Masliah, E. (1998). nN0S expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer’s Disease. Exp. Neurol. 150, 14-20. doi: 10.1006/exnr.1997.6751
127. Usardi, A., Pooler, A. M., Seereeram, A., Reynolds, C. H., Derkinderen, P., Anderton, B., et al. (2011). Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J. 278, 2927-2937. doi: 10.1111/j.1742-4658.2011.08218.x
128. Vana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., and Binder, L. I. (2011). Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Am. J. Pathol. 179, 2533-2550. doi: 10.1016/j.ajpath.2011.07.044
129. van de Nes, J. A., Nafe, R., and Schlote, W. (2008). Non-tau based neuronal degeneration in Alzheimer’s disease -an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res. 1213, 152-165. doi: 10.1016/j.brainres.2008.03.043
130. von Bergen, M., Barghorn, S., Biernat, J., Mandelkow, E.-M., and Mandelkow, E. (2005). Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim. Biophys. Acta 1739, 158-166. doi: 10.1016/j.bbadis.2004.09.010
131. Vuono, R., Winder-Rhodes, S., de Silva, R., Cisbani, G., Drouin-Ouellet, J., et al. REGISTRY Investigators of the European Huntington’s Disease Network. (2015). The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain 138(Pt 7), 1907-1918. doi: 10.1093/brain/awv107
132. Walsh, D. M., and Selkoe, D. J. (2007). A beta oligomers -a decade of discovery. J. Neurochem. 101, 1172-1184. doi: 10.1111/j.1471-4159.2006.04426.x
133. Wang, J., Dickson, D. W., Trojanowski, J. Q., and Lee, V. M. (1999). The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp. Neurol. 158, 328-337. doi: 10.1006/exnr.1999.7085
134. Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., et al. (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714. doi: 10.1126/science.1062382
135. Woodhouse, A., West, A. K., Chuckowree, J. A., Vickers, J. C., and Dickson, T. C. (2005). Does beta-amyloid plaque formation cause structural injury to neuronal processes? Neurotox Res. 7, 5-15. doi: 10.1007/BF03033772
136. Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., Figueroa, H., et al. (2013). Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288, 1856-1870. doi: 10.1074/jbc.M112.394528
137. Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., et al. (2011). In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110-13117. doi: 10.1523/JNEUR0SCI.2569-11.2011
138. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. doi: 10.1016/j.neuron.2007.01.010
139. Zempel, H., and Mandelkow, E. M. (2012). Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener. Dis. 10, 64-72. doi: 10.1159/000332816
140. Zempel, H., Thies, E., Mandelkow, E., and Mandelkow, E. M. (2010). Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30, 11938-11950. doi: 10.1523/JNEUR0SCI.2357-10.2010